首页 > 用药指导 > 文章详情

Ambisome(安必素)的适应症和用法用量

发布时间:2025-04-22 15:18:39 阅读:1092 来源:问药网
分享至

分享到微信朋友圈

×

打开微信,点击底部的“发现”,

使用“扫一扫”即可将网页分享至朋友圈。

安必素

安必素 生产厂家:迈兰(Mylan)制药有限公司 功能主治:一线抗真菌药物,治疗深部真菌感染有效率高 用法用量:用法用量  静脉用药:开始静脉滴注时先试以1~5mg或按体重一次0.02~0.1mg/kg给药,以后根据患者耐受情况每日或隔日增加5mg,当增至一次 0.6~0.7mg/kg时即可暂停增加剂量,此为一般治疗量。  成人最高一日剂量不超过1mg/kg,每日或隔1~2日给药1次,累积总量 1.5~3.0g,疗程1~3个月,也可长至6个月,视病情及疾病种类而定。  对敏感真菌感染宜采用较小剂量,即成人一次20~30mg,疗程仍宜长。  鞘内给药:首次0.05~0.1mg,以后渐增至每次0.5mg,最大量一次不超过1mg,每周给药2~3次,总量15mg左右。  鞘内给药时宜与小剂量地塞米松或琥珀酸氢化可的松同时给与,并需用脑脊液反复稀释药液,边稀释边缓慢注入以减少不良反应。  局部用药:气溶吸入时成人每次5~10mg,用灭菌注射用水溶解成0.2%~0.3%溶液应用;超声雾化吸入时本品浓度为0.01%~0.02%,每日吸入2~3次,每次吸入5~10ml;持续膀胱冲洗时每日以两性霉素B 5mg加入1000ml灭菌注射用水中,按每小时注入40ml速度进行冲洗,共用5~10日。  静脉滴注或鞘内给药时,均先以灭菌注射用水10ml配制本品50mg,或5ml配制25mg,然后用5%葡萄糖注射液稀释(不可用氯化钠注射液,因可产生沉淀),滴注液的药物浓度不超过10mg/100ml,避光缓慢静滴,每次滴注时间需6小时以上,稀释用葡萄糖注射液的pH值应在4.2以上。  鞘内注射时可取5mg/ml浓度的药液1ml,加5%葡萄糖注射液19ml稀释,使最终浓度成250μg/ml。  注射时取所需药液量以脑脊液5~30ml反复稀释,并缓慢注入。  鞘内注射液的药物浓度不可高于25mg/100ml,pH值应在4.2以上。
查看详情

Ambisome(安必素)的适应症和用法用量,安必素(Amphotericin)适用于患有深部真菌感染的患者;因肾损伤或药物毒性而不能使用有效剂量的两性霉素B的患者,或已经接受过治疗无效的患者均可使用。安必素(Amphotericin)建议在新的治疗疗程之前给予测试剂量。可以服用少量的AmBisome输液(例如1mg)约10分钟,然后停止服用,并在接下来的30分钟内仔细观察患者。如果没有严重的过敏或类过敏反应,则可以继续输注AmBisome剂量。

Ambisome (安必素) is a medication used to treat fungal infections. It is an injectable form of the antifungal agent called amphotericin B. The drug works by interfering with the growth and reproduction of certain fungi, thereby helping to eliminate the infection. Ambisome is prescribed for a variety of fungal infections, including those caused by Aspergillus, Candida, and Cryptococcus species. This article will outline the indications and dosage guidelines for Ambisome.

1. Indications for Ambisome:

Ambisome is indicated for the treatment of serious systemic fungal infections. It is commonly used when infections do not respond to other antifungal medications or when the infection is considered life-threatening. Some of the specific indications for Ambisome include:

Invasive aspergillosis: a fungal infection primarily affecting individuals with weakened immune systems, such as those undergoing chemotherapy or organ transplantation.

Candidemia and other invasive Candida infections: these are severe infections caused by the Candida species, which can affect various organs and systems in the body.

Cryptococcal meningitis: a fungal infection affecting the membranes surrounding the brain and spinal cord. It is commonly seen in individuals with HIV/AIDS or other immunocompromised conditions.

Empirical therapy in febrile neutropenic patients: Ambisome may be considered as a first-line treatment in patients with neutropenia (low white blood cell count) and fever of unknown origin, in which a fungal infection is suspected.

2. Dosage and Administration of Ambisome:

The dosage and administration of Ambisome may vary depending on the specific indication, severity of the infection, and individual patient factors. It is typically given as an intravenous infusion, meaning it is administered directly into a vein. The recommended dosage is determined by the patient's weight and renal function.

For most indications, the usual starting dose of Ambisome is 3 mg per kg of body weight per day. The infusion is usually given over 1 to 2 hours, once daily.

The duration of treatment depends on the type and severity of the infection. It is typically continued until the infection is controlled and the patient's condition improves. The treatment course can range from several weeks to several months.

Adjustments may be necessary for patients with impaired renal function. The dose should be reduced or the dosing interval extended, in accordance with the prescribing physician's recommendations.

Ambisome is typically administered in a hospital setting under close medical supervision. Healthcare professionals monitor the patient for any potential side effects and regularly evaluate the effectiveness of the treatment.

3. Special Considerations and Precautions:

When using Ambisome, it is important to consider the following:

Ambisome should be used with caution in patients with pre-existing kidney problems or other conditions that may cause electrolyte imbalances.

It is essential to monitor patients' renal function during treatment to minimize the risk of kidney damage.

Ambisome can cause side effects, including fever, chills, nausea, and anemia. These should be promptly reported to the healthcare provider.

Prior to starting Ambisome, the healthcare provider should assess for any potential drug interactions or contraindications.

4. Conclusion:

Ambisome is an important medication in the treatment of serious fungal infections. By adhering to the recommended indications, dosage guidelines, and precautions, healthcare professionals can optimize the therapeutic benefits of Ambisome while minimizing potential risks. It is essential for patients to follow their healthcare provider's instructions and report any concerns or side effects during treatment.